Share：
Share this content in WeChat
X
[Chinese][PDF]351
• Clinical Article •
Diagnostic value of cardiac magnetic resonance feature tracking technique in non-dilated left ventricular cardiomyopathy
YAN Chunlong  ZHUANG Baiyan  XU Lei 

Cite this article as: YAN C L, ZHUANG B Y, XU L. Diagnostic value of cardiac magnetic resonance feature tracking technique in non-dilated left ventricular cardiomyopathy[J]. Chin J Magn Reson Imaging, 2025, 16(5): 143-148. DOI:10.12015/issn.1674-8034.2025.05.022.


[Abstract] Objective To investigate the value of cardiac magnetic resonance feature tracking (CMR-FT) in evaluating non-dilated left ventricular cardiomyopathy (NDLVC).Materials and Methods A retrospective analysis was performed on 50 patients with NDLVC who underwent CMR examination in Beijing Anzhen Hospital from January 2022 to November 2024, defined as the NDLVC group, and another 25 patients without cardiovascular disease and no abnormal CMR manifestations in the same period were selected as the control group. Left ventricular 3D global strain parameters of all subjects were obtained by CVI42 post-processing software. The receiver operating characteristic (ROC) curve was utilized to assess the diagnostic efficacy of strain parameters in distinguishing the NDLVC group from the control group.Results Compared with the control group, LVESV and LV mass at ED in NDLVC patients increased, and the difference was statistically significant (P < 0.05); While the absolute values of LVSV, LVCO, LVEF, GRS (3D), GCS (3D) and GLS (3D) decreased, and the difference was statistically significant (P < 0.05). ROC curve analysis showed that the critical values for GRS (3D), GCS (3D) and GLS (3D) identification of the two groups were 35.34%, -16.88% and -10.55%, and the sensitivity was 72.00%, 46.00% and 58.00%, respectively. The specificity was 72.00%, 96.00%, 76.00%, and AUC was 0.778, 0.713, 0.706, respectively.Conclusions CMR-FT technique has certain diagnostic value for NDLVC patients, GRS (3D) sensitivity is higher, GCS (3D) specificity is higher.
[Keywords] nondilated left ventricular cardiomyopathy；cardiac magnetic resonance feature tracking technology；myocardial stress；magnetic resonance imaging；cardiac function

YAN Chunlong   ZHUANG Baiyan   XU Lei*  

Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China

Corresponding author: XU L, E-mail: leixu2001@hotmail.com

Conflicts of interest   None.

Received  2025-02-15
Accepted  2025-05-10
DOI: 10.12015/issn.1674-8034.2025.05.022
Cite this article as: YAN C L, ZHUANG B Y, XU L. Diagnostic value of cardiac magnetic resonance feature tracking technique in non-dilated left ventricular cardiomyopathy[J]. Chin J Magn Reson Imaging, 2025, 16(5): 143-148. DOI:10.12015/issn.1674-8034.2025.05.022.

[1]
ARBELO E, PROTONOTARIOS A, GIMENO J R, et al. 2023 ESC guidelines for the management of cardiomyopathies[J]. Eur Heart J, 2023, 44(37): 3503-3626. DOI: 10.1093/eurheartj/ehad194.
[2]
MONDA E, MURREDDA A, RUBINO M, et al. Aetiology and clinical manifestations of patients with non-dilated left ventricular cardiomyopathy[J]. Eur J Heart Fail, 2024, 26(12): 2579-2581. DOI: 10.1002/ejhf.3470.
[3]
REDDY Y N V, BORLAUG B A, GERSH B J. Management of atrial fibrillation across the spectrum of heart failure with preserved and reduced ejection fraction[J]. Circulation, 2022, 146(4): 339-357. DOI: 10.1161/CIRCULATIONAHA.122.057444.
[4]
DZIEWIĘCKA E, WINIARCZYK M, WIŚNIOWSKA-ŚMIAŁEK S, et al. Comparison of clinical course and outcomes between dilated and hypokinetic non-dilated cardiomyopathy[J]. Cardiology, 2023, 148(5): 395-401. DOI: 10.1159/000531534.
[5]
CASTRICHINI M, DE LUCA A, DE ANGELIS G, et al. Magnetic resonance imaging characterization and clinical outcomes of dilated and arrhythmogenic left ventricular cardiomyopathies[J]. J Am Coll Cardiol, 2024, 83(19): 1841-1851. DOI: 10.1016/j.jacc.2024.02.041.
[6]
EDA Y, NABETA T, IIKURA S, et al. Non-dilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes[J]. ESC Heart Fail, 2024, 11(3): 1463-1471. DOI: 10.1002/ehf2.14711.
[7]
NARDUCCI M L, SCACCIAVILLANI R, NANO R L, et al. Prognostic value of electroanatomic-guided endomyocardial biopsy in patients with myocarditis, arrhythmogenic cardiomyopathy and non dilated left ventricular cardiomyopathy[J/OL]. Int J Cardiol, 2024, 416: 132489 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/39187071/. DOI: 10.1016/j.ijcard.2024.132489.
[8]
HAMMERSLEY D J, JONES R E, OWEN R, et al. Phenotype, outcomes and natural history of early-stage non-ischaemic cardiomyopathy[J]. Eur J Heart Fail, 2023, 25(11): 2050-2059. DOI: 10.1002/ejhf.3037.
[9]
MONTEIRO P, PEIXOTO T, RODRIGUES P, et al. CT and MR imaging of cardiomyopathies in clinical practice-an approach after an abnormal echocardiogram or electrocardiogram[J/OL]. Echocardiography, 2025, 42(2): e70104 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/39963998/. DOI: 10.1111/echo.70104.
[10]
BOTIS I, BAZMPANI M A, DAIOS S, et al. The role of cardiovascular magnetic resonance imaging in the assessment of mitral regurgitation[J/OL]. Diagnostics (Basel), 2024, 14(6): 644 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/38535064/. DOI: 10.3390/diagnostics14060644.
[11]
CORADUCCI F, DE ZAN G, FEDELE D, et al. Cardiac magnetic resonance in advanced heart failure[J/OL]. Echocardiography, 2024, 41(6): e15849 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/38535064/. DOI: 10.1111/echo.15849.
[12]
POPA O A, AMZULESCU M, BUGEAC C, et al. Cardiovascular magnetic resonance imaging in myocardial disease[J/OL]. Cureus, 2024, 16(4): e58688 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/38774162/. DOI: 10.7759/cureus.58688.
[13]
SANTORO F, VITALE E, RAGNATELA I, et al. Multidisciplinary approach in cardiomyopathies: From genetics to advanced imaging[J]. Heart Fail Rev, 2024, 29(2): 445-462. DOI: 10.1007/s10741-023-10373-8.
[14]
WANG T K M, BRIZNEDA M V, KWON D H, et al. Reference ranges, diagnostic and prognostic utility of native T1 mapping and extracellular volume for cardiac amyloidosis: a meta-analysis[J]. J Magn Reson Imaging, 2021, 53(5): 1458-1468. DOI: 10.1002/jmri.27459.
[15]
SHEN L T, SHI R, YANG Z G, et al. Progress in cardiac magnetic resonance feature tracking for evaluating myocardial strain in type-2 diabetes mellitus[J]. Curr Diabetes Rev, 2024, 20(8): 98-109. DOI: 10.2174/0115733998277127231211063107.
[16]
MOZAFARYBAZARGANY M, SALMANIPOUR A, GHAFFARI JOLFAYI A, et al. Value of cardiac magnetic resonance feature-tracking in Arrhythmogenic Cardiomyopathy (ACM): a systematic review and meta-analysis[J/OL]. IJC Heart Vasc, 2024, 53: 101455 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/39228971/. DOI: 10.1016/j.ijcha.2024.101455.
[17]
CAI Q Y, ZHAO Z K, GAO J, et al. Normal values for atrial deformation measured by feature-tracking cardiac MRI: a meta-analysis[J]. J Magn Reson Imaging, 2025, 61(2): 882-898. DOI: 10.1002/jmri.29465.
[18]
ZLIBUT A, COJOCARU C, ONCIUL S, et al. Cardiac magnetic resonance imaging in appraising myocardial strain and biomechanics: a current overview[J/OL]. Diagnostics (Basel), 2023, 13(3): 553 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/36766658/. DOI: 10.3390/diagnostics13030553.
[19]
YANG W J, XU J, ZHU L Y, et al. Myocardial strain measurements derived from MR feature-tracking: influence of sex, age, field strength, and vendor[J]. JACC Cardiovasc Imaging, 2024, 17(4): 364-379. DOI: 10.1016/j.jcmg.2023.05.019.
[20]
HU M, SHEN Y, YU H, et al. Prognostic value of cardiac magnetic resonance imaging feature tracking technology in patients with light chain amyloidosis[J/OL]. Clin Radiol, 2024, 79(2): e239-e246 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/37953095/. DOI: 10.1016/j.crad.2023.10.016.
[21]
FILOMENA D, VANDENBERK B, DRESSELAERS T, et al. Cardiac diagnoses and long-term outcomes in ring-like late gadolinium enhancement evaluated by cardiac magnetic resonance[J]. Eur Heart J Cardiovasc Imaging, 2025, 26(5): 841-852. DOI: 10.1093/ehjci/jeaf055.
[22]
LEO I, DELLEGROTTAGLIE S, SCATTEIA A, et al. CarDiac magnEtic resonance for prophylactic implantable-cardioVerter defibrillAtor ThErapy in non-dilated left ventricular cardiomyopathy: a sub-study from the DERIVATE registry[J/OL]. Eur Heart J Cardiovasc Imaging, 2025: jeaf043 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/39899463/. DOI: 10.1093/ehjci/jeaf043.
[23]
ZHANG X P, WANG C, HUANG Y T, et al. Unveiling the diagnostic value of strain parameters across all 4 cardiac chambers in patients with acute myocarditis with varied ejection fraction: a cardiovascular magnetic resonance feature-tracking approach[J/OL]. J Am Heart Assoc, 2024, 13(13): e032781 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/38934873/. DOI: 10.1161/JAHA.123.032781.
[24]
KOIZUMI S, KEIICHI I, SAKAI T, et al. Cardiac magnetic resonance feature tracking analysis for change in right ventricular function after cardioplegic arrest[J]. Heart Lung Circ, 2024, 33(10): 1457-1464. DOI: 10.1016/j.hlc.2024.05.007.
[25]
MARTÍNEZ-VIVES P, CECCONI A, VERA A, et al. Usefulness of tissue tracking by cardiac magnetic resonance to predict events in patients with hypertrophic cardiomyopathy[J/OL]. Am J Cardiol, 2022, 174: 126-135 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/35525624/. DOI: 10.1016/j.amjcard.2022.03.024.
[26]
MATUSIK P S, MIKRUT K, BRYLL A, et al. Cardiac magnetic resonance imaging in diagnostics and cardiovascular risk assessment[J/OL]. Diagnostics (Basel), 2025, 15(2): 178 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/39857062/. DOI: 10.3390/diagnostics15020178.
[27]
MAŁEK Ł A, MAZURKIEWICZ Ł, MARSZAŁEK M, et al. Deformation parameters of the heart in endurance athletes and in patients with dilated cardiomyopathy-a cardiac magnetic resonance study[J/OL]. Diagnostics (Basel), 2021, 11(2): 374 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/33671723/. DOI: 10.3390/diagnostics11020374.
[28]
TANG L, WU X, PENG P F, et al. Value of cardiac magnetic resonance feature tracking in the evaluation of ventricular function in uncomplicated obesity subjects[J]. Chin J Magn Reson Imag, 2023, 14(3): 88-94. DOI: 10.12015/issn.1674-8034.2023.03.015.
[29]
SHEN M T, YANG Z G, GUO Y K, et al. Impact of functional mitral regurgitation on left ventricular strain in nonischemic dilated cardiomyopathy patients with type 2 mellitus diabetes: a magnetic resonance feature tracking study[J]. J Magn Reson Imaging, 2025, 61(2): 911-925. DOI: 10.1002/jmri.29469.
[30]
SUBRAMANIAN V, KESHVANI N, SEGAR M W, et al. Association of global longitudinal strain by feature tracking cardiac magnetic resonance imaging with adverse outcomes among community-dwelling adults without cardiovascular disease: The Dallas Heart Study[J]. Eur J Heart Fail, 2024, 26(2): 208-215. DOI: 10.1002/ejhf.3158.
[31]
YANG X Y, WU J, ZHU L N, et al. Application of MR myocardial strain technique in the diagnosis and differential diagnosis of hypertrophic cardiomyopathy[J]. Chin J Magn Reson Imag, 2022, 13(2): 10-15, 21. DOI: 10.12015/issn.1674-8034.2022.02.003.
[32]
CIONCA C, ZLIBUT A, AGOSTON R, et al. Evaluating the clinical utility of left ventricular strains in severe AS: a pilot study with feature-tracking cardiac magnetic resonance[J/OL]. Biomedicines, 2024, 12(9): 2104 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/39335618/. DOI: 10.3390/biomedicines12092104.
[33]
CHO S K S, DARBY J R T, WILLIAMS G K, et al. Post-myocardial infarction remodeling and hyperkinetic remote myocardium in sheep measured by cardiac MRI feature tracking[J]. J Magn Reson Imaging, 2025, 61(3): 1323-1335. DOI: 10.1002/jmri.29496.
[34]
MEYER S L, RIDDERBOS F S, WOLFF D, et al. Serial cardiovascular magnetic resonance feature tracking indicates early worsening of cardiac function in Fontan patients[J/OL]. Int J Cardiol, 2020, 303: 23-29 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/31918854/. DOI: 10.1016/j.ijcard.2019.12.041.
[35]
LIU W Y, ZHU Y S, FENG C J, et al. Early cardiac involvement detected by cardiac magnetic resonance feature tracking in idiopathic inflammatory myopathy with preserved ejection fraction[J]. Int J Cardiovasc Imaging, 2023, 39(1): 183-194. DOI: 10.1007/s10554-022-02715-8.
[36]
NEGRI F, SANNA G D, DI GIOVANNA G, et al. Cardiac magnetic resonance feature-tracking identifies preclinical abnormalities in hypertrophic cardiomyopathy sarcomere gene mutation carriers[J/OL]. Circ Cardiovasc Imaging, 2024, 17(4): e016042 [2025-02-14]. https://pubmed.ncbi.nlm.nih.gov/38563190/. DOI: 10.1161/CIRCIMAGING.123.016042.
[37]
ZHUANG B Y, LI S, WANG H, et al. Value of CMR feature-tracking imaging in discriminating subtypes of cardiac amyloidosis[J]. Chin J Magn Reson Imag, 2024, 15(2): 23-29, 62. DOI: 10.12015/issn.1674-8034.2024.02.004.

PREV Value of diffusion kurtosis imaging combined with conventional MRI in the differential diagnosis of benign and malignant thyroid nodules
NEXT Evaluation of the influence of left ventricular myocardial fibrosis on biventricular function in patients with coronary artery disease based on cardiac magnetic resonance feature tracking
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn